1941 Results
Sort By:
Published on October 8, 2014
CRO med fusion is partnering with genomics technology and services provider GenomOncology to optimize treatment strategies based on the patient's disease state and tumor profile by integrating GenomOncology's technology platform—the GO Clinical Workbench™—and support services with med fusion's soon-to-be expanded solid tumor disease-specific panels. This pairing, the firms say, would…
Published on October 7, 2014
A project team led by Benjamin Darbro, M.D., Ph.D., director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory at the University of Iowa Hospital and Clinics, has won the inaugural Appistry Pipeline Challenge for developing and executing a pipeline designed to reduce the costs and turnaround times associated with…
Published on September 24, 2014
While sequencing entire human genomes is an important achievement of next-generation sequencing (NGS) technology, many clinical research goals can be achieved by sequencing a subset of the genome or genes of interest. Targeted sequencing pools large numbers of individual samples to sequence at the same time. This approach lowers the…
Published on September 19, 2014
Thermo Fisher Scientific completed the listing of its Ion PGM Dx next-generation sequencing (NGS) system with the FDA for clinical use as a class II medical device. Intended for targeted sequencing of human genomic DNA using peripheral whole-blood samples, the system supports the development and implementation of user-defined NGS diagnostic…
Published on September 10, 2014
It was inspiring to listen to Howard J. Jacob, Ph.D., professor of physiology and human and molecular genetics at Medical College of Wisconsin, speaking a few years back about successfully treating a young boy with an extreme form of inflammatory bowel disease using genome sequencing. It just shows that with…
Published on September 8, 2014
Four cancer research institutes have joined with Illumina to form a consortium that will recommend standards for applying next-generation sequencing to cancer tumors. The new Actionable Genome Consortium (AGC) said it aims to help oncologists and pathologists determine the best therapeutic and testing strategies for improving patient outcomes. Joining Illumina…
Published on September 5, 2014
Laboratory Corporation of America® Holdings (LabCorp) launched a new business, Enlighten Health Genomics, that builds on the diagnostic potential of next-generation sequencing (NGS) technology. The company said it aims to make genetic profiles a routine part of clinical decisions. Enlighten Health Genomics combines LabCorp’s infrastructure and capabilities with a team…
Published on August 27, 2014
The National Institutes of Health has issued a final NIH Genomic Data Sharing (GDS) policy to promote data sharing as a way to speed the translation of data into knowledge, products, and procedures that improve health while protecting the privacy of research participants. The final policy was posted in the…
Published on August 21, 2014
Illumina formed collaborative partnerships with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing (NGS)-based oncology test system. It will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool…
Published on August 13, 2014
Thirteen years after the completion of the Human Genome Project, an increasing number of genomic applications, including next-generation sequencing (NGS), are poised for clinical use. Fulfilling the promise of genomics to improve health in the real world requires a public health perspective. As genomics reaches the bedside, a public health…
Published on August 13, 2014
Next-generation sequencing (NGS) not only continues to make steady advances in the molecular diagnosis of cancers, it also seems to fit perfectly with our current knowledge of the oncogenome. In particular, by making it possible to screen the entire coding sequence of cancer-related genes, NGS overcomes a key problem—cancer predisposition…
Published on August 8, 2014
Advancing the work of The Cancer Genome Atlas (TCGA), a large team of researchers from multiple institutions performed a comprehensive analysis of molecular data from thousands of patients representing 12 different types of cancer. The analysis pointed to an alternative system for classifying cancer. Instead of defining cancers according to…
Published on July 25, 2014
Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds under development that target the SF3B1 gene. Mutations of this gene, which Qiagen said…
Published on July 24, 2014
Cypher Genomics and Illumina have made a pact to co-promote Illumina's sequencing technology, the NextBio platform for data analytics and storage, and Cypher's Coral™ biomarker discovery service to pharmaceutical companies. The firms, through Illumina's sales team, will be promoting the products and service together as part of a solution that,…
Published on July 21, 2014
Berry Genomics chose Illumina's next-generation sequencing technology as the platform on which Berry will aim to secure Chinese Food and Drug Administration (CFDA) regulatory approval for clinical applications. The goal is to expand access to NGS-based tests in China. The companies say have co-developed an NGS system to provide a…